+

MX2023009560A - Solidos cristalinos del inhibidor de mek n-((r)-2,3-dihidroxipropo xi)-3,4-difluoro-2-(2-fluoro-4-yodo-fenilamino)-benzamida y sus usos. - Google Patents

Solidos cristalinos del inhibidor de mek n-((r)-2,3-dihidroxipropo xi)-3,4-difluoro-2-(2-fluoro-4-yodo-fenilamino)-benzamida y sus usos.

Info

Publication number
MX2023009560A
MX2023009560A MX2023009560A MX2023009560A MX2023009560A MX 2023009560 A MX2023009560 A MX 2023009560A MX 2023009560 A MX2023009560 A MX 2023009560A MX 2023009560 A MX2023009560 A MX 2023009560A MX 2023009560 A MX2023009560 A MX 2023009560A
Authority
MX
Mexico
Prior art keywords
dihydroxypropoxy
benzamide
difluoro
fluoro
iodophenylamino
Prior art date
Application number
MX2023009560A
Other languages
English (en)
Inventor
Kristin Patterson
Jiping Liu
Ricky Wayne Couch
Peter Gregory Varlashkin
Mai Li
Yonghong Gan
Original Assignee
Springworks Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Springworks Therapeutics Inc filed Critical Springworks Therapeutics Inc
Publication of MX2023009560A publication Critical patent/MX2023009560A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/10—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to carbon atoms of six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente descripción se refiere a: a) formas cristalinas de N-((R)-2,3-dihidroxipropoxi)-3,4- difluoro-2-(2-fluoro-4-yodo-feni lamino)-benzamida; b) composiciones farmacéuticas que comprenden una o más formas cristalinas de N-((R)-2,3-dihidroxipropoxi)-3,4-d ifluoro-2-(2-fluoro-4- yodo-fenilamino)-benzamida y, opcionalmente, uno o más portadores farmacéuticamente aceptables; c) métodos para el tratamiento de un tumor, un cáncer, o un trastorno por Rasopatía, mediante la administración de una o más formas cristalinas de N-((R)-2,3-dihidroxipropoxi)-3,4- difluoro-2-(2-fluoro-4-yodo-fenilamino)-benzamida a un sujeto que lo necesita; y métodos para la producción de la Forma IV esencialmente pura de N-((R)-2,3-dihidroxipropoxi)-3,4-difluoro-2- (2- fluoro-4-yodo-fenilamino)-benzamida.
MX2023009560A 2021-02-17 2021-02-17 Solidos cristalinos del inhibidor de mek n-((r)-2,3-dihidroxipropo xi)-3,4-difluoro-2-(2-fluoro-4-yodo-fenilamino)-benzamida y sus usos. MX2023009560A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2021/018381 WO2022177557A1 (en) 2021-02-17 2021-02-17 Crystalline solids of mek inhibitor n-((r)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide and uses thereof

Publications (1)

Publication Number Publication Date
MX2023009560A true MX2023009560A (es) 2023-10-25

Family

ID=74860569

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023009560A MX2023009560A (es) 2021-02-17 2021-02-17 Solidos cristalinos del inhibidor de mek n-((r)-2,3-dihidroxipropo xi)-3,4-difluoro-2-(2-fluoro-4-yodo-fenilamino)-benzamida y sus usos.

Country Status (11)

Country Link
EP (1) EP4294526A1 (es)
JP (1) JP2024509759A (es)
KR (1) KR20230147139A (es)
CN (1) CN117083264A (es)
AR (1) AR124911A1 (es)
AU (1) AU2021428512A1 (es)
CA (1) CA3207513A1 (es)
IL (1) IL305078A (es)
MX (1) MX2023009560A (es)
TW (1) TW202302526A (es)
WO (1) WO2022177557A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL305079A (en) * 2021-02-17 2023-10-01 Springworks Therapeutics Inc Dispersible formulations of N-((R)-3,2-dihydroxypropoxy)-4,3-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide and their uses
EP4526286A1 (en) 2022-05-17 2025-03-26 Assia Chemical Industries Ltd. Solid state forms of mirdametinib and process for preparation thereof
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU2503A (sh) * 2000-07-19 2006-05-25 Warner-Lambert Company Oksigenovani estri 4-jodo fenilamino benzhidroksamskih kiselina
WO2004045617A1 (en) * 2002-11-15 2004-06-03 Warner-Lambert Company Llc Combination chemotherapy comprising a mek inhibitor and capecitabine for treating cancer
CA2542210A1 (en) * 2003-10-21 2005-05-06 Warner-Lambert Company Llc Polymorphic form of n-[(r)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide
WO2006134469A1 (en) * 2005-06-14 2006-12-21 Warner-Lambert Company Llc Methods of preparing mek inhibitor
WO2007042885A2 (en) * 2005-10-07 2007-04-19 Pfizer Products Inc. Therapeutic combination comprising methotrexate and a specified inhibitor of mek1 and mek2
RS61653B2 (sr) * 2014-02-07 2024-10-31 Global Blood Therapeutics Inc Kristalni polimorfni oblik slobodne baze 2-hidroksi-6-((2-(1-izopropil-1h-pirazol-5-il)piridin-3-il)metoksi)benzaldehid
US11084780B1 (en) * 2021-02-17 2021-08-10 Springworks Therapeutics, Inc. Crystalline solids of MEK inhibitor N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
US11066358B1 (en) * 2021-02-17 2021-07-20 Warner-Lambert Company Llc Compositions of essentially pure form IV of N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof

Also Published As

Publication number Publication date
TW202302526A (zh) 2023-01-16
WO2022177557A1 (en) 2022-08-25
KR20230147139A (ko) 2023-10-20
EP4294526A1 (en) 2023-12-27
JP2024509759A (ja) 2024-03-05
CN117083264A (zh) 2023-11-17
IL305078A (en) 2023-10-01
AU2021428512A1 (en) 2023-09-21
AR124911A1 (es) 2023-05-17
CA3207513A1 (en) 2022-08-25

Similar Documents

Publication Publication Date Title
MX2023009560A (es) Solidos cristalinos del inhibidor de mek n-((r)-2,3-dihidroxipropo xi)-3,4-difluoro-2-(2-fluoro-4-yodo-fenilamino)-benzamida y sus usos.
JP5148271B2 (ja) 疼痛処置のためのカプサイシノイド、局所麻酔薬および／または鎮痒薬を含有する処方物
BRPI0415710A (pt) formas polimórficas de n-[(r)-2,3-dihidróxi-propóxi]-3,4-diflúor-2-(2-flúor-4-io dofenilamino)-benzamida
MX2023009555A (es) Composiciones de la forma iv esencialmente pura de n-((r)-2,3-dihidroxipropoxi)-3,4-difluoro-2-(2-fluoro-4-yodo-feni lamino)-benzamida y usos de estas.
GEP20043160B (en) Biaryl Ether Derivatives, Pharmaceutical Compositions Containing Them and Their Use as Monoamine Reuptake Inhibitors
WO2003103603A3 (en) NEW FORMIATE-TYPE SALT OF O-DESMETHYLVENLAFAXINE
MX2024006074A (es) Inhibidor de parp1 selectivo y aplicacion del mismo.
MX2009008228A (es) N-adamantil benzamidas como inhibidores de la dehidrogenasa 11-beta-hidroxiesteroide.
MX2022009700A (es) Compuesto de sulfonamida o sulfinamida que tiene el efecto de inducir la degradacion de la proteina de bromodominio 4 (brd4) y el uso farmaceutico del mismo.
MX2025005014A (es) Inhibidor del inflamosoma nlrp3 y uso de este
ATE427931T1 (de) Analgetische verbindungen, deren synthese und pharmazeutische zusammensetzungen, die diese enthalten
PH12023552963A1 (en) Compositions and methods for the treatment of depression
EP4560024A3 (en) Deuterated analogs of d-serine and uses thereof
RU2013129917A (ru) Новое соединение и его применение в медицине
WO2021231314A8 (en) Methods of treating covid-19 using tetracycline compounds
MX2023009559A (es) Formulaciones dispersables de n-((r)-2,3-dihidroxipropoxi)-3,4-dif luoro-2-(2-fluoro-4-yodo-fenilamino)-benzamida y sus usos.
WO2021242844A8 (en) Grk2 inhibitors and uses thereof
MX2023003458A (es) Nuevos compuestos.
TN2011000456A1 (en) Treatment of pancreatic cancer
JP2020536048A5 (es)
GB1444733A (en) Gentlamicin derivatives and process for their production
AR045423A1 (es) Combinaciones de analiticos y antidepresivos
WO2020247819A3 (en) Methods of treatment with aminolevulinic acid synthase 2 (alas2) modulators
RS51676B (en) USE OF AGOMELATIN FOR OBTAINING MEDICINES FOR SMITH-MAGENIS SYNDROME TREATMENT
Freedman et al. Safety and efficacy of teriflunomide in patients with relapsing multiple sclerosis treated with interferon beta
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载